Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 68

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 68
---
 under the Relief License Agreement. There was no deferred revenue related to this agreement as of June 30, 2025, and 2024.Accounts and Other ReceivablesAccounts and other receivables consist of receivables from product sales of MIPLYFFA and OLPRUVA, reimbursements received under the French AC, royalties or net sales milestone payments generated under the AZSTARYS License Agreement, and other receivables due to the Company. Receivables under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable third-party costs as well as milestones and royalties on product sales. Receivables are recorded for commercial sales of MIPLYFFA and OLPRUVA to a single specialty pharmacy and product sales under the French AC. The Company provides reserves against receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company’s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve. Accounts and other receivables consist of the following (in thousands): June 30,2025December 31,2024Commercial accounts receivable$9,801 $4,010 Receivables related to product reimbursements6,842 5,380 Royalties and milestones accounts receivable1,183 786 Other receivables440 333 Total receivables$18,266 $10,509 

 As of June 30, 2025, and December 31, 2024, no reserve or allowance for doubtful accounts had been established. 

G.    Stock and Warrants

Authorized, Issued, and Outstanding Common SharesAs of June 30, 2025, and December 31, 2024, the Company had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 56,659,896 and 55,246,401 shares of common stock were issued as of June 30, 2025, and December 31, 2024, respectively, and 55,084,204 and 53,670,709 shares of common stock were outstanding as of June 30, 2025, and December 31, 2024, respectively.As of June 30,